Payment overview · 2025
General Payments
$29.22
2 reported records · 2 companies
Healthcare provider profile · identity verified
David Brice Wheat, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLINTON, MS · NPI 1487697561
Verified facts
What the public records show
CMS Open Payments records show David Brice Wheat, MD received $29.22 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 50.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.72 | 50.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.50 | 49.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $29.22 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 309 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 83 |
| Meloxicam | Meloxicam | 192 | 68 |
| Omeprazole | Omeprazole | 177 | 49 |
| Lisinopril | Lisinopril | 172 | 41 |
| Metformin Hcl | Metformin Hcl | 135 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 34 |
| Gabapentin | Gabapentin | 119 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 21 |
| Eliquis | Apixaban | 81 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 28 |
| Losartan Potassium | Losartan Potassium | 72 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 22 |
| Simvastatin | Simvastatin | 64 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 14 |
| Glimepiride | Glimepiride | 53 | 15 |
| Synthroid | Levothyroxine Sodium | 53 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 17 |
| Furosemide | Furosemide | 49 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Atenolol | Atenolol | 48 | 13 |
| Trazodone Hcl | Trazodone Hcl | 48 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 13 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 39 |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 11 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 13 |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Prednisone | Prednisone | 19 | 18 |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Clarithromycin | Clarithromycin | 16 | 15 |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Ozempic | Semaglutide | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 11 |
| Valsartan | Valsartan | 13 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $29.22 · 2 records | PFIZER INC. | PAXLOVID, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error